The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: Design and methods

Alan S. Go, Chirag R. Parikh, T. Alp Ikizler, Steven Coca, Edward D. Siew, Vernon M. Chinchilli, Chi Yuan Hsu, Amit X. Garg, Michael Zappitelli, Kathleen D. Liu, W. Brian Reeves, Nasrollah Ghahramani, Prasad Devarajan, Georgia Brown Faulkner, Thida C. Tan, Paul L. Kimmel, Paul Eggers, John B. Stokes

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Background: The incidence of acute kidney injury (AKI) has been increasing over time and is associated with a high risk of short-term death. Previous studies on hospital-acquired AKI have important methodological limitations, especially their retrospective study designs and limited ability to control for potential confounding factors. Methods: The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study was established to examine how a hospitalized episode of AKI independently affects the risk of chronic kidney disease development and progression, cardiovascular events, death, and other important patient-centered outcomes. This prospective study will enroll a cohort of 1100 adult participants with a broad range of AKI and matched hospitalized participants without AKI at three Clinical Research Centers, as well as 100 children undergoing cardiac surgery at three Clinical Research Centers. Participants will be followed for up to four years, and will undergo serial evaluation during the index hospitalization, at three months post-hospitalization, and at annual clinic visits, with telephone interviews occurring during the intervening six-month intervals. Biospecimens will be collected at each visit, along with information on lifestyle behaviors, quality of life and functional status, cognitive function, receipt of therapies, interim renal and cardiovascular events, electrocardiography and urinalysis. Conclusions: ASSESS-AKI will characterize the short-term and long-term natural history of AKI, evaluate the incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI, and identify a subset of high-risk patients who could be targeted for future clinical trials to improve outcomes after AKI.

Original languageEnglish (US)
Article number22
JournalBMC Nephrology
Volume11
Issue number1
DOIs
StatePublished - Aug 31 2010

Fingerprint

Acute Kidney Injury
Hospitalization
Aptitude
Urinalysis
Ambulatory Care
Chronic Renal Insufficiency
Research
Cognition
Thoracic Surgery
Disease Progression
Life Style
Electrocardiography
Retrospective Studies
Biomarkers
Quality of Life
Clinical Trials
Urine
Prospective Studies
Interviews
Kidney

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Go, Alan S. ; Parikh, Chirag R. ; Ikizler, T. Alp ; Coca, Steven ; Siew, Edward D. ; Chinchilli, Vernon M. ; Hsu, Chi Yuan ; Garg, Amit X. ; Zappitelli, Michael ; Liu, Kathleen D. ; Reeves, W. Brian ; Ghahramani, Nasrollah ; Devarajan, Prasad ; Faulkner, Georgia Brown ; Tan, Thida C. ; Kimmel, Paul L. ; Eggers, Paul ; Stokes, John B. / The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study : Design and methods. In: BMC Nephrology. 2010 ; Vol. 11, No. 1.
@article{b9911dc11bf740659db50625fda83808,
title = "The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: Design and methods",
abstract = "Background: The incidence of acute kidney injury (AKI) has been increasing over time and is associated with a high risk of short-term death. Previous studies on hospital-acquired AKI have important methodological limitations, especially their retrospective study designs and limited ability to control for potential confounding factors. Methods: The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study was established to examine how a hospitalized episode of AKI independently affects the risk of chronic kidney disease development and progression, cardiovascular events, death, and other important patient-centered outcomes. This prospective study will enroll a cohort of 1100 adult participants with a broad range of AKI and matched hospitalized participants without AKI at three Clinical Research Centers, as well as 100 children undergoing cardiac surgery at three Clinical Research Centers. Participants will be followed for up to four years, and will undergo serial evaluation during the index hospitalization, at three months post-hospitalization, and at annual clinic visits, with telephone interviews occurring during the intervening six-month intervals. Biospecimens will be collected at each visit, along with information on lifestyle behaviors, quality of life and functional status, cognitive function, receipt of therapies, interim renal and cardiovascular events, electrocardiography and urinalysis. Conclusions: ASSESS-AKI will characterize the short-term and long-term natural history of AKI, evaluate the incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI, and identify a subset of high-risk patients who could be targeted for future clinical trials to improve outcomes after AKI.",
author = "Go, {Alan S.} and Parikh, {Chirag R.} and Ikizler, {T. Alp} and Steven Coca and Siew, {Edward D.} and Chinchilli, {Vernon M.} and Hsu, {Chi Yuan} and Garg, {Amit X.} and Michael Zappitelli and Liu, {Kathleen D.} and Reeves, {W. Brian} and Nasrollah Ghahramani and Prasad Devarajan and Faulkner, {Georgia Brown} and Tan, {Thida C.} and Kimmel, {Paul L.} and Paul Eggers and Stokes, {John B.}",
year = "2010",
month = "8",
day = "31",
doi = "10.1186/1471-2369-11-22",
language = "English (US)",
volume = "11",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

Go, AS, Parikh, CR, Ikizler, TA, Coca, S, Siew, ED, Chinchilli, VM, Hsu, CY, Garg, AX, Zappitelli, M, Liu, KD, Reeves, WB, Ghahramani, N, Devarajan, P, Faulkner, GB, Tan, TC, Kimmel, PL, Eggers, P & Stokes, JB 2010, 'The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: Design and methods', BMC Nephrology, vol. 11, no. 1, 22. https://doi.org/10.1186/1471-2369-11-22

The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study : Design and methods. / Go, Alan S.; Parikh, Chirag R.; Ikizler, T. Alp; Coca, Steven; Siew, Edward D.; Chinchilli, Vernon M.; Hsu, Chi Yuan; Garg, Amit X.; Zappitelli, Michael; Liu, Kathleen D.; Reeves, W. Brian; Ghahramani, Nasrollah; Devarajan, Prasad; Faulkner, Georgia Brown; Tan, Thida C.; Kimmel, Paul L.; Eggers, Paul; Stokes, John B.

In: BMC Nephrology, Vol. 11, No. 1, 22, 31.08.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study

T2 - Design and methods

AU - Go, Alan S.

AU - Parikh, Chirag R.

AU - Ikizler, T. Alp

AU - Coca, Steven

AU - Siew, Edward D.

AU - Chinchilli, Vernon M.

AU - Hsu, Chi Yuan

AU - Garg, Amit X.

AU - Zappitelli, Michael

AU - Liu, Kathleen D.

AU - Reeves, W. Brian

AU - Ghahramani, Nasrollah

AU - Devarajan, Prasad

AU - Faulkner, Georgia Brown

AU - Tan, Thida C.

AU - Kimmel, Paul L.

AU - Eggers, Paul

AU - Stokes, John B.

PY - 2010/8/31

Y1 - 2010/8/31

N2 - Background: The incidence of acute kidney injury (AKI) has been increasing over time and is associated with a high risk of short-term death. Previous studies on hospital-acquired AKI have important methodological limitations, especially their retrospective study designs and limited ability to control for potential confounding factors. Methods: The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study was established to examine how a hospitalized episode of AKI independently affects the risk of chronic kidney disease development and progression, cardiovascular events, death, and other important patient-centered outcomes. This prospective study will enroll a cohort of 1100 adult participants with a broad range of AKI and matched hospitalized participants without AKI at three Clinical Research Centers, as well as 100 children undergoing cardiac surgery at three Clinical Research Centers. Participants will be followed for up to four years, and will undergo serial evaluation during the index hospitalization, at three months post-hospitalization, and at annual clinic visits, with telephone interviews occurring during the intervening six-month intervals. Biospecimens will be collected at each visit, along with information on lifestyle behaviors, quality of life and functional status, cognitive function, receipt of therapies, interim renal and cardiovascular events, electrocardiography and urinalysis. Conclusions: ASSESS-AKI will characterize the short-term and long-term natural history of AKI, evaluate the incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI, and identify a subset of high-risk patients who could be targeted for future clinical trials to improve outcomes after AKI.

AB - Background: The incidence of acute kidney injury (AKI) has been increasing over time and is associated with a high risk of short-term death. Previous studies on hospital-acquired AKI have important methodological limitations, especially their retrospective study designs and limited ability to control for potential confounding factors. Methods: The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study was established to examine how a hospitalized episode of AKI independently affects the risk of chronic kidney disease development and progression, cardiovascular events, death, and other important patient-centered outcomes. This prospective study will enroll a cohort of 1100 adult participants with a broad range of AKI and matched hospitalized participants without AKI at three Clinical Research Centers, as well as 100 children undergoing cardiac surgery at three Clinical Research Centers. Participants will be followed for up to four years, and will undergo serial evaluation during the index hospitalization, at three months post-hospitalization, and at annual clinic visits, with telephone interviews occurring during the intervening six-month intervals. Biospecimens will be collected at each visit, along with information on lifestyle behaviors, quality of life and functional status, cognitive function, receipt of therapies, interim renal and cardiovascular events, electrocardiography and urinalysis. Conclusions: ASSESS-AKI will characterize the short-term and long-term natural history of AKI, evaluate the incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI, and identify a subset of high-risk patients who could be targeted for future clinical trials to improve outcomes after AKI.

UR - http://www.scopus.com/inward/record.url?scp=77955972575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955972575&partnerID=8YFLogxK

U2 - 10.1186/1471-2369-11-22

DO - 10.1186/1471-2369-11-22

M3 - Article

C2 - 20799966

AN - SCOPUS:77955972575

VL - 11

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 22

ER -